wall thickness, and diastolic dysfunction, independent of other known causes of LVH such as hypertension (6,7). These effects may be mediated through a variety of metabolic abnormalities that coexist with or result from obesity such as insulin resistance, elevated leptin levels (or leptin resistance), decreased levels of adiponectin, activation of the reninangiotensin-aldosterone system, and lipotoxicity (5).
that 1 in 5 adults will develop HF over their lifetime (1) . This emergent HF burden is in part attributable to aging of the population and improved survival from atherosclerotic cardiovascular disease and other chronic cardiovascular diseases. In addition, obesity is increasingly recognized as a key driver of the increase in HF prevalence, due to both staggering increases in rates of obesity and better understanding of the direct and indirect mechanisms through which obesity contributes to HF risk.
In a landmark study of 5,881 participants from the Framingham Heart Study, Kenchaiah et al. (2) demonstrated that for every 1 kg/m 2 increase in body mass index (BMI), the risk of HF increased by 5% and 7% in men and women, respectively. These epidemi- Novo Nordisk, and Diadexus. Dr. Neeland has reported that he has no relationships relevant to the contents of this paper to disclose. delemos@utsouthwestern.edu.
